Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin ( or cisplatin ) or ramucirumab ( 10 mg/kg ) plus pemetrexed and carboplatin ( or cisplatin ) once every 3 weeks .